• Organon will present a new Phase 3 analysis of VTAMA for moderate-to-severe atopic dermatitis on November 14, 2026, in Phoenix.
• The presentation at the American College of Allergy, Asthma & Immunology meeting highlights consistent efficacy over time across patient subgroups.
• The analysis evaluates differences in affected skin area and other baseline characteristics.
• VTAMA cream is indicated for atopic dermatitis in patients aged 2 years and older, as well as plaque psoriasis in adults.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Organon & Co. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261105927902) on November 05, 2026, and is solely responsible for the information contained therein.